Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALA: Glatiramer Acetate 40 mg TIW in RRMS
NCT01067521Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2010
- Primary completion
- May 2012
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Annualized Rate of Confirmed Relapses at 12 months. Started Jun 2010; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01067521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01067521.